The Medicines Company and Bristol-Myers Squibb Begin Global Alliance for Recothrom(R)

The Medicines Company and Bristol-Myers Squibb Begin Global Alliance for 
PARSIPPANY, NJ -- (Marketwire) -- 02/08/13 --   The Medicines Company
(NASDAQ: MDCO) announced today that the global license and two-year
collaboration for Recothrom(R), a recombinant thrombin approved by
the U.S. Food and Drug Administration for use as a topical hemostat
to control non-arterial bleeding during surgical procedures,
established with Bristol-Myers Squibb Company, has become effective.  
The agreement was first announced in December 2012. The companies
have satisfied all required regulatory and closing conditions.  
Glenn Sblendorio, President and Chief Financial Officer of The
Medicines Company, said, "We look forward to the start of our global
license and collaboration for Recothrom. We believe that completing
this deal is another step to establish The Medicines Company as a
leader in acute and intensive care medicine globally."  
About Recothrom(R) 
 Recothrom is a surgical hemostat that is applied
topically to stop bleeding during surgery. Its active ingredient is
recombinant human thrombin ("rThrombin") and the product is indicated
as an aid to hemostasis whenever control of bleeding by standard
surgical techniques (such as suture, ligature, or cautery) is
ineffective or impractical. Recothrom is part of a class of surgical
hemostats commonly referred to as "active" hemostats. Other classes
of surgical hemostats include mechanical hemostats, flowable
hemostats and fibrin sealants. Recothrom was approved in the United
States in January 2008 and in Canada in December 2010.  
About The Medicines Company
 The Medicines Company (NASDAQ: MDCO)
provides medical solutions to improve health outcomes for patients in
acute and intensive care hospitals worldwide. These solutions
comprise medicines and knowledge that directly impact the survival
and well being of critically ill patients. The Medicines Company's
website is 
Forward-Looking Statements
 Statements contained in this press
release about The Medicines Company that are not purely historical,
and all other statements that are not purely historical, may be
deemed to be forward-looking statements for purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act
of 1995. Without limiting the foregoing, the words "believes,"
"anticipates" and "expects" and similar expressions are intended to
identify forward-looking statements, including the Company's
expectations regarding the effect of the transaction on the Company's
earnings per share and pursuit of approvals for Recothrom in
jurisdictions other than the United States and Canada. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results, levels of
activity, performance or achievements to be materially different from
those expressed or implied by these forward-looking statements.
Important factors that may cause or contribute to such differences
include the extent of the commercial success of Recothrom, the
ability of the Company to obtain regulatory approvals of Recothrom in
jurisdictions other than the United States and Canada, risks related
to the Company's dependence on Bristol-Myers Squibb to manufacture
and supply Recothrom products during the collaboration term, the
ability of Bristol-Myers Squibb and the Company to complete the
transfer of the manufacturing assets if the Company exercises its
option to acquire such assets, the Company's ability to successfully
manufacture Recothrom products if it exercises its option to acquire
the manufacturing assets, the ability of the Company to obtain third
party consents necessary for the transfer of the acquired assets, the
ability of the Company to successfully integrate the Recothrom
business with its other businesses, the Company's ability to develop
its global operations and penetrate foreign markets, whether the
Company's products will advance in the clinical trials process on a
timely basis or at all, whether the Company will make regulatory
submissions for product candidates on a timely basis, whether its
regulatory submissions will receive approvals from regulatory
agencies on a timely basis or at all, whether physicians, patients
and other key decision makers will accept clinical trial results,
risks associated with the establishment of international operations,
and such other factors as are set forth in the risk factors detailed
from time to time in the Company's periodic reports and registration
statements filed with the Securities and Exchange Commission
including, without limitation, the risk factors detailed in the
Company's Quarterly Report on Form 10-Q filed on November 9, 2012,
which are incorporated herein by reference. The Company specifically
disclaims any obligation to update these forward-looking statements.  
The Medicines Company 
Michael Mitchell 
Press spacebar to pause and continue. Press esc to stop.